Innate Pharma SA (IPHA) intrinsic value & 10-year financials
Innate Pharma SA (IPHA) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue shrank 18.0% a year to €9.0M, with an average return on invested capital of 49.8%.
- Graham intrinsic value
- —
- Revenue (FY2025)
- €9.0M
- Revenue growth (10-yr CAGR)
- -18.0%
- ROIC (10-yr avg)
- 49.8%
- Free cash flow (FY2025)
- -€52.9M
IPHA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | €9.0M | -€49.2M | -€0.55 | -€52.9M | -599.8% | 839.3% |
| FY2024 | €20.1M | -€49.5M | -€0.61 | -€7.3M | -256.3% | -169.8% |
| FY2023 | €61.6M | -€7.6M | -€0.09 | -€32.9M | -20.6% | -23.9% |
| FY2022 | €57.7M | -€58.1M | -€0.73 | -€19.7M | -99.6% | -71.1% |
| FY2021 | €24.7M | -€52.8M | -€0.66 | -€59.4M | -193.6% | -36.3% |
| FY2020 | €70.5M | -€64.0M | -€0.81 | -€52.7M | -88.1% | -33.2% |
| FY2019 | €85.8M | -€20.8M | -€0.31 | €33.7M | -31.5% | -14.1% |
| FY2018 | €94.0M | €3.0M | €0.05 | -€33.4M | 5.5% | 4.1% |
| FY2017 | €44.0M | -€48.4M | -€0.89 | -€51.0M | -90.8% | -46.5% |
| FY2016 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in EUR.
Executive summary
Innate Pharma SA revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Innate Pharma SA 10-year average ROIC is N/A; capital efficiency cannot be assessed from the available history.
Innate Pharma SA capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Innate Pharma SA is modeled at -18.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-1.19 per share.